Hadar Goldvaser

12PUBLICATIONS
16CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsEpidemiological methodsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 15, 2026
Oral Estrogen Receptor Degraders Compared to Standard Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.

|Jun 26, 2026
A phase 1b study of chemo-immunotherapy with pegylated liposomal doxorubicin and Pembrolizumab in estrogen receptor positive metastatic breast cancer.

|Nov 19, 2024
ER + HER2- early-stage breast cancer: association of HER2 expression, tumor characteristics, and outcomes.

Hadar Goldvaser, Rinat Yerushalmi, Raz Mutai

|Feb 12, 2024
The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy.

Raz Mutai, Iryna Kuchuk, Alexandra Goldshtein

|Mar 21, 2021
Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.

Michal Sternschuss, Rinat Yerushalmi, Ramy R Saleh

|Feb 12, 2021
Incidence of lung cancer following pneumonia in smokers: a population-based study.

D Shepshelovich, N Barda, H Goldvaser

Pageof 2

Frequent Collaborators

2 joint publications

Assaf Moore

2 joint publications

Albert Grinshpun

1 joint publications

D Shepshelovich

1 joint publications

T Diker-Cohen